Form 4: Lyell COO Sells Shares for Tax Obligations

Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, sold 1,236 shares of common stock on February 11, 2026, to cover tax withholding obligations related to vested restricted stock units.

Summary

• Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, Inc. (LYEL), reported a sale of common stock.
• The transaction occurred on February 11, 2026.
• A total of 1,236 shares were sold at a weighted average price of $23.39 per share, with the sale price ranging from $23.3939 to $24.7850 per share.
• The sale was non-discretionary, executed automatically to cover tax withholding obligations arising from the settlement of performance-based vested restricted stock units.
• Following this transaction, Mr. Hill directly beneficially owns 17,795 shares of Lyell Immunopharma common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a non-discretionary transaction to cover tax obligations from vested restricted stock units, which is a common and expected occurrence for executives receiving equity compensation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that this is a routine insider transaction for tax purposes, a common occurrence across industries when restricted stock units vest, and is often executed under a pre-arranged 10b5-1 trading plan to avoid accusations of insider trading.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in company fundamentals or management's confidence.

Key Dates

Recommendation

The sale by the Chief Operating Officer is a non-discretionary transaction to cover tax obligations from vested restricted stock units, which is a common occurrence and does not reflect a change in management's confidence or the company's fundamentals. Therefore, a 'hold' recommendation is appropriate as this event alone does not provide new information to alter an investment thesis.

Keywords

Lyell Immunopharma, LYEL, Stephen J. Hill, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, COO, 10b5-1 Plan